{"id":72494,"date":"2026-08-14T11:59:48","date_gmt":"2026-08-14T03:59:48","guid":{"rendered":"https:\/\/flcube.com\/?p=72494"},"modified":"2026-08-14T11:59:49","modified_gmt":"2026-08-14T03:59:49","slug":"nmpa-releases-draft-implementation-rules-for-the-national-key-rd-program-public-comment-open-through-12-sept-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72494","title":{"rendered":"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has released for public comment the <strong>&#8220;Implementation Rules for the National Key R&amp;D Program under the Purview of the National Medical Products Administration (Draft for Comments)&#8221;<\/strong>, a regulatory framework designed to ensure the effective organization and implementation of the <strong>National Key R&amp;D Program<\/strong>. The draft rules are open for public comments from <strong>13 August to 12 September 2026<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-policy-snapshot\" class=\"wp-block-heading\">Policy Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Issuing Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Document<\/strong><\/td><td>Implementation Rules for the National Key R&amp;D Program (Draft for Comments)<\/td><\/tr><tr><td><strong>Drafting Date<\/strong><\/td><td>11 Aug 2026<\/td><\/tr><tr><td><strong>Public Comment Period<\/strong><\/td><td>13 Aug \u2013 12 Sept 2026<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Organization and implementation of the National Key R&amp;D Program under NMPA purview<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-management-structure-amp-guiding-principles\" class=\"wp-block-heading\">Management Structure &amp; Guiding Principles<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Two\u2011Level Management:<\/strong> The National Key R&amp;D Program is managed at two levels \u2014 <strong>key projects<\/strong> and <strong>sub\u2011projects<\/strong>.<\/li>\n\n\n\n<li><strong>Guiding Principles:<\/strong><\/li>\n\n\n\n<li><strong>Demand\u2011orientation<\/strong> and dynamic deployment<\/li>\n\n\n\n<li><strong>Open innovation<\/strong> and collaborative research<\/li>\n\n\n\n<li><strong>Goal\u2011oriented management<\/strong> and accelerated application<\/li>\n\n\n\n<li><strong>Coordinated planning<\/strong> and clearly assigned responsibilities<\/li>\n\n\n\n<li><strong>Unified Digital Oversight:<\/strong> The entire process of key projects is integrated into the unified <strong>National Science and Technology Management Information System<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-governance-amp-organizational-model\" class=\"wp-block-heading\">Governance &amp; Organizational Model<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Responsibility Division:<\/strong> The <strong>NMPA<\/strong> takes the lead, fully leveraging an <strong>inter\u2011departmental coordination mechanism<\/strong>, and establishing a <strong>special working group<\/strong> and <strong>expert panel<\/strong>.<\/li>\n\n\n\n<li><strong>Deployment Model:<\/strong> An organizational approach combining <strong>fixed timeline deployment<\/strong> with <strong>agile deployment<\/strong> for research tasks.<\/li>\n\n\n\n<li><strong>Team Selection:<\/strong> Flexible methods to select outstanding research teams.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-lifecycle-management-amp-eligibility-requirements\" class=\"wp-block-heading\">Lifecycle Management &amp; Eligibility Requirements<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Requirement<\/th><\/tr><\/thead><tbody><tr><td><strong>Project Lifecycle Coverage<\/strong><\/td><td>Project initiation, process management, comprehensive performance evaluation, fund management, supervision and assessment<\/td><\/tr><tr><td><strong>Undertaking Entities<\/strong><\/td><td>Independent legal entities registered in <strong>Mainland China for at least one year<\/strong>, with strong research capabilities, adequate conditions, and good credit standing<\/td><\/tr><tr><td><strong>Principal Investigators<\/strong><\/td><td>Generally <strong>no older than 60<\/strong>, meeting relevant requirements on limitations<\/td><\/tr><tr><td><strong>Additional Emphasis<\/strong><\/td><td>Commercialization of scientific and technological achievements; establishment of confidentiality systems<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Institutional Framework for Pharma R&amp;D Funding:<\/strong> The draft rules formalize how China channels state R&amp;D funding through the <strong>NMPA<\/strong>, with direct implications for drug developers, academic institutions, and research hospitals competing for National Key R&amp;D Program support.<\/li>\n\n\n\n<li><strong>Commercialization Emphasis:<\/strong> The explicit focus on <strong>commercialization of scientific and technological achievements<\/strong> signals Beijing&#8217;s intent to convert publicly funded research into marketable therapies and products.<\/li>\n\n\n\n<li><strong>Eligibility Gatekeeping:<\/strong> Requirements on entity registration, credit standing, and principal\u2011investigator age are designed to channel funding toward established, accountable research teams.<\/li>\n\n\n\n<li><strong>Next Step:<\/strong> Stakeholders have until <strong>12 September 2026<\/strong> to submit comments before finalization \u2014 a window for industry input on implementation details.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the finalization of the draft rules, the public comment process, and the future organization of the National Key R&amp;D Program under NMPA purview. Actual outcomes may differ based on comments received, policy revisions, and inter\u2011departmental coordination.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA) has released for public comment the &#8220;Implementation Rules for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[14],"class_list":["post-72494","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA) has released for public comment the &quot;Implementation Rules for the National Key R&amp;D Program under the Purview of the National Medical Products Administration (Draft for Comments)&quot;, a regulatory framework designed to ensure the effective organization and implementation of the National Key R&amp;D Program. The draft rules are open for public comments from 13 August to 12 September 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72494\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA) has released for public comment the &quot;Implementation Rules for the National Key R&amp;D Program under the Purview of the National Medical Products Administration (Draft for Comments)&quot;, a regulatory framework designed to ensure the effective organization and implementation of the National Key R&amp;D Program. The draft rules are open for public comments from 13 August to 12 September 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72494\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-14T03:59:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-14T03:59:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72494#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72494\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026\",\"datePublished\":\"2026-08-14T03:59:48+00:00\",\"dateModified\":\"2026-08-14T03:59:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72494\"},\"wordCount\":489,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NMPA\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72494#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72494\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72494\",\"name\":\"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-14T03:59:48+00:00\",\"dateModified\":\"2026-08-14T03:59:49+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) has released for public comment the \\\"Implementation Rules for the National Key R&D Program under the Purview of the National Medical Products Administration (Draft for Comments)\\\", a regulatory framework designed to ensure the effective organization and implementation of the National Key R&D Program. The draft rules are open for public comments from 13 August to 12 September 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72494#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72494\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72494#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) has released for public comment the \"Implementation Rules for the National Key R&D Program under the Purview of the National Medical Products Administration (Draft for Comments)\", a regulatory framework designed to ensure the effective organization and implementation of the National Key R&D Program. The draft rules are open for public comments from 13 August to 12 September 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72494","og_locale":"en_US","og_type":"article","og_title":"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026","og_description":"China's National Medical Products Administration (NMPA) has released for public comment the \"Implementation Rules for the National Key R&D Program under the Purview of the National Medical Products Administration (Draft for Comments)\", a regulatory framework designed to ensure the effective organization and implementation of the National Key R&D Program. The draft rules are open for public comments from 13 August to 12 September 2026.","og_url":"https:\/\/flcube.com\/?p=72494","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-14T03:59:48+00:00","article_modified_time":"2026-08-14T03:59:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72494#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72494"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026","datePublished":"2026-08-14T03:59:48+00:00","dateModified":"2026-08-14T03:59:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72494"},"wordCount":489,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NMPA"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72494#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72494","url":"https:\/\/flcube.com\/?p=72494","name":"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-14T03:59:48+00:00","dateModified":"2026-08-14T03:59:49+00:00","description":"China's National Medical Products Administration (NMPA) has released for public comment the \"Implementation Rules for the National Key R&D Program under the Purview of the National Medical Products Administration (Draft for Comments)\", a regulatory framework designed to ensure the effective organization and implementation of the National Key R&D Program. The draft rules are open for public comments from 13 August to 12 September 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72494#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72494"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72494#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Releases Draft Implementation Rules for the National Key R&amp;D Program \u2013 Public Comment Open Through 12 Sept 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72494"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72494\/revisions"}],"predecessor-version":[{"id":72495,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72494\/revisions\/72495"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}